Nivolumab/relatlimab-associated cutaneous immune-related adverse events in patients treated for advanced melanoma: Supplemental file
Published: 17 February 2025| Version 1 | DOI: 10.17632/jvw7f27cch.1
Contributors:
, , , , , Description
Supplementary tables I (multivariable analysis of patient characteristics associated with developing cirAEs on nivolumab-relatlimab) and II (choice of therapy for the management of first, second, and third cirAEs)
Files
Categories
Dermatology, Oncology, Immune Response